Researchers have proposed a unifying mathematical framework that helps explain why many successful multimodal AI systems work ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Variational AI, the company behind Enki™, an advanced foundation model for small molecule drug discovery, today ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Variational AI, developer of the Enki™ generative artificial intelligence (AI) platform for drug discovery, today announced a project with Merck Research ...

Vancouver firm's AI platform will generate chemical compounds based on Merck’s therapeutic targets. A Vancouver startup using artificial intelligence (AI) to discover new drugs has struck a deal with ...

Merck & Co. is taking a look at a generative AI platform. As an early user of Variational AI’s technology, the Big Pharma will assess the ability of the platform to generate novel small molecules that ...

Merck & Co. has doubled down on its partnership with Variational AI, striking a deal worth up to $349 million to collaborate on small molecule candidates against two targets. Variational disclosed a ...

Merck & Co. Inc., (NYSE:MRK) is one of the best conservative stocks to buy now. On September 23, the company confirmed a strategic collaboration with Variational AI to leverage its Enki Platform in ...

Variational AI CEO Handol Kim's company has a platform that uses the language of chemistry to create drug recipes | Rob Kruyt Multinational drug developer Merck is partnering with a Vancouver-based ...